Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Lethal Company Minimum System Requirements
China wins bronze in League of Legends but all eyes on South Korea in gold-medal match
Horrified mum says stranger 'spoke to her son for weeks' after hacking baby monitor
Put Down the Phone: How to Unplug With Google's Digital Wellbeing for Android
Save £100 on the Garmin Forerunner 245 this Prime Day
Markiplier: 2023 net worth and ex-girlfriends of YouTuber set to star in 'Iron Lung'
This 4-in-1 charging station is just $26
Tristan Tate takes aim at Mark Zuckerberg as he pleads for fan support to secure access to Threads, trolls say 'best of luck playing victim'